IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

FDA prohibits Ranbaxy API plant from producing and distributing products for US market

4:15 AM MST | January 24, 2014 | Deepti Ramesh

The US Food and Drug Administration (FDA) announced on 23 January that it has notified Ranbaxy Laboratories (Gurgaon, India), that it is prohibited from manufacturing and distributing active pharmaceutical ingredients (APIs) from its facility at Toansa, India, for FDA-regulated drug products. The Toansa facility is now subject to certain terms of a consent decree of permanent injunction entered against Ranbaxy in January 2012. The decree contains provisions to ensure compliance with current good manufacturing practice (cGMP) requirements at Ranbaxy facilities at...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers

 

 

 













 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2014 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa